Matrix of Alpha Edge Metrics
Matrix of Alpha Edge Metrics
Hims & Hers: Growth Story or Just Clever Marketing? Hims & Hers Health just dropped its Q3 2025 numbers, and on the surface, they look pretty good. Revenue's up nearly 50% year-over-year, hitting $599 million. Adjusted EBITDA is also up, a...
Hims & Hers Health (HIMS) is riding a wave of investor optimism, fueled by talks with Novo Nordisk about offering Wegovy (both oral and injectable) on its platform. The stock jumped nearly 6% in pre-market trading on this news. But is this...
When I was at MIT, we used to talk endlessly about the "killer app"—that one piece of software that would change everything. We imagined elegant code, brilliant algorithms, and world-altering platforms. But we often missed the most importan...
The market doesn’t do nuance well. On any given day, a stock is either a rocket ship to the moon or a cautionary tale. For Hims & Hers Health (NYSE: HIMS), the narrative has been almost exclusively the former. A 39% surge in a single month...